Kristoffer Bissessar
Director/Board Member presso BIOINVENT INTERNATIONAL AB
Patrimonio netto: 23 848 $ in data 31/03/2024
Provenienza dei contatti di primo grado di Kristoffer Bissessar
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Biotechnology | 26 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Kristoffer Bissessar tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| ONCOLYTICS BIOTECH INC. | Biotechnology | Director/Board Member Director/Board Member | |
BioPhausia AB
 BioPhausia AB Medical DistributorsDistribution Services BioPhausia AB operates as a pharmaceutical company. It markets and distributes original drugs, generic products, and the parallel-imported medicines. The company is headquartered in Stockholm, Sweden. | Medical Distributors | Chairman | |
| Nyenrode Business Universiteit | College/University | Graduate Degree | |
| MEDIVIR AB | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| University of Oxford | College/University | Undergraduate Degree | |
Institut Pasteur
 Institut Pasteur Investment Trusts/Mutual FundsMiscellaneous The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
Van Herk Investments BV
 Van Herk Investments BV Investment ManagersFinance Van Herk Investments BV (VHI) is the private equity investment arm of the Van Herk Groep BV, based in Rotterdam. The parent firm was established in the 1950s as a family business with a focus on real estate investments. VHI invests in listed and unlisted firms across diverse sectors primarily in The Netherlands. | Investment Managers | Director of Finance/CFO Private Equity Investor | |
| University of Cambridge | College/University | Masters Business Admin | |
Debiopharm International SA
 Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| The University of California, San Francisco | College/University | Corporate Officer/Principal | |
Agendia NV
 Agendia NV Medical/Nursing ServicesHealth Services Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
| University College London | College/University | Doctorate Degree | |
| University of Lund | College/University | Undergraduate Degree Masters Business Admin Undergraduate Degree | |
| Erasmus University Rotterdam | College/University | Undergraduate Degree Graduate Degree Doctorate Degree | |
| Université Paris 1 Panthéon-Sorbonne | College/University | Doctorate Degree | |
| Max-Planck-Institute for Molecular Genetics | College/University | Doctorate Degree | |
Cancer Research UK
 Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Apposite Capital LLP
 Apposite Capital LLP Investment ManagersFinance Apposite Capital LLP (Apposite Capital) is a private equity arm of Mizuho Financial Group, Inc. founded in 2016 by David Porter. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Corporate Officer/Principal | |
| IMMUNE DESIGN CORP | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Immunexpress Pty Ltd.
 Immunexpress Pty Ltd. Medical SpecialtiesHealth Technology Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia. | Medical Specialties | Director/Board Member | |
Novo Seeds
 Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Investment Managers | Director of Investments | |
Agendia, Inc.
 Agendia, Inc. Pharmaceuticals: MajorHealth Technology Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Respiratorius AB
 Respiratorius AB Pharmaceuticals: MajorHealth Technology Respiratorius AB engages in the development of drug candidates for Chronic Obstructive Pulmonary Disease, asthma, and cancer. The company was founded by Lars Christer Fedrik Fåhraeus and Staffan Skogwall in 1999 and is headquartered in Lund, Sweden. | Pharmaceuticals: Major | Chairman | |
| Pfizer AB | Chief Executive Officer | ||
| ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member | |
Minervax ApS
 Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Medical Specialties | Director/Board Member | |
| Universidad del Rosario | College/University | Doctorate Degree | |
Pcovery ApS
 Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Epsilon-3 Bio Ltd
 Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Other | Director/Board Member | |
| MENDUS AB | Biotechnology | Director/Board Member Director/Board Member Chairman | |
| Centre d'Immunologie Pierre Fabre | Corporate Officer/Principal | ||
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Avilex Pharma ApS
 Avilex Pharma ApS Pharmaceuticals: MajorHealth Technology Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
| OBSEVA SA | Pharmaceuticals: Major | Director/Board Member | |
SkylineDx BV
 SkylineDx BV Medical/Nursing ServicesHealth Services SkylineDx BV develops molecular diagnostic tests for blood cancers. The firm focuses on the development and commercialization of gene signature-based diagnostic tests, which assist healthcare professionals in making personalized treatment decisions for individual patients. Its products include MMprofiler and AMLprofiler. The company was founded by Dharminder S. Chahal and Bob Löwenberg in 2005 and is headquartered in Rotterdam, the Netherlands. | Medical/Nursing Services | Director of Finance/CFO Director/Board Member Chief Executive Officer | |
Glionova AB
 Glionova AB Pharmaceuticals: MajorHealth Technology Glionova AB develops cancer treatment drugs. The firm is a drug discovery and development company. It offers GLN-1001 product. The company was founded by Lars G. J. Hammarström and Patrik Ernfors in 2014 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
CCP Investment Partners AB
 CCP Investment Partners AB Investment ManagersFinance CCP Investment Partners AB (Ceder Capital) is a private equity firm headquartered in Stockholm, Sweden. The firm was founded in 2014. | Investment Managers | Founder | |
Inthera Bioscience AG
 Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | Biotechnology | Director/Board Member | |
IO Biotech ApS
 IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Biotechnology | Director/Board Member | |
| INVENTIVA | Biotechnology | Director/Board Member | |
| AEC Skyline Holding BV | Director/Board Member | ||
Adero AB
 Adero AB Engineering & ConstructionIndustrial Services Part of Storskogen Group AB, Adero AB is a private company that provides heating, ventilation, air conditioning, and building installation services. The company is based in Stockholm, Sweden. Adero was acquired by Storskogen Group AB on October 11, 2021. Andreas Benetoft has been the CEO of the Swedish company since 2013. | Engineering & Construction | Director/Board Member | |
| Stichting Op Klompen Begonnen | Investment Trusts/Mutual Funds | Director/Board Member | |
| Stichting Start2Cure | Investment Trusts/Mutual Funds | Director/Board Member | |
de Hoben GmbH
 de Hoben GmbH Real Estate DevelopmentFinance de Hoben GmbH is a private company that was founded in 2017 and engages in the buying and selling of land, buildings, and apartments. The company is based in Dusseldorf, Germany. | Real Estate Development | Director/Board Member | |
| Campus Fraxinus Excelsior BV | Director/Board Member | ||
| Ht Projecktentwicklung GmbH | Director/Board Member | ||
Affinicon ApS
 Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | Pharmaceuticals: Major | Director/Board Member |
Statistiche
Distribuzione geografica
| Svezia | 11 |
| Paesi Bassi | 10 |
| Danimarca | 10 |
| Regno Unito | 7 |
| Francia | 5 |
Settori
| Health Technology | 21 |
| Consumer Services | 11 |
| Finance | 7 |
| Miscellaneous | 4 |
| Health Services | 3 |
Posizioni
| Director/Board Member | 134 |
| Independent Dir/Board Member | 31 |
| Chairman | 30 |
| Corporate Officer/Principal | 30 |
| Chief Executive Officer | 21 |
Contatti più connessi
| Insiders | |
|---|---|
| Nanna Liebach Lüneborg | 29 |
| Dharminder Singh Chahal | 25 |
| Thomas O. Hecht | 24 |
| Bernd Seizinger | 23 |
| Leonard Kruimer | 22 |
| Vincent Ossipow | 22 |
| Erik Esveld | 15 |
| Niklas Prager | 14 |
| Lars Ingelmark | 13 |
| An van Es-Johansson | 13 |
| Martin Welschof | 12 |
| Michael Oredsson | 12 |
| Andres McAllister | 9 |
| Natalie Berner | 6 |
| Cecilia Hofvander | 5 |
- Borsa valori
- Insiders
- Kristoffer Bissessar
- Connessioni Società
